Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Navinta, LLC

Shrenik K Shah

William K Hagmann

Paul E Finke

Malcolm MacCoss

Sander G Mills

Conrad P Dorn

Jeffrey John Hale

James B Doherty

Linus S Lin

Tamara Ladduwahetty

Ravindra N Guthikonda

Timothy Harrison

Philippe L Durette

Brian John Williams

Linda L Chang

Hongbo Qi

Richard A Mumford

Thomas J Lanza, Jr

Mark Stewart Chambers

Charles G Caldwell

Malcolm Maccoss

James Patrick Jewell

Quang T Truong

Kothandaraman Shankaran

George A Doherty

Dong-Ming Shen

Raymond A Firestone

Soumya P Sahoo

Ping Liu

Dooseop Kim

Kevin Tyler Chapman

Jennifer L Loebach

Kevan R Thompson

Helen M Armstrong

Amjad Ali

Mark T Goulet

Michael Man-Chu Lo

Lin Yan

Timothy J Henderson

Christopher W Plummer

Mark Stuart Chambers

Yuan-Ching P Chiang

Brent Whitehead

Morris Zimmerman

Zhiqiang Guo

Bryan Oates

Bonnie M Ashe

Kerry A Hilfiker

Karla L Furman

Ravi N Guthikonda

Ravi P Nargund

Thomas F Walsh

William F Hoffman

Jian Liu

Shuwen He

Mahendra R Patel

Christopher L Lynch

Robert K Baker

Liangqin Guo

John S Debenham

Theodore M Kamenecka

Christina B Madsen-Duggan

Hiroo Koyama

Richard B Toupence

Edward Metzger

Zhong Lai

Laura C Meurer

Christopher Alan Willoughby

Jun Wang

Daniel J Miller

Craig K Esser

Albert J Robichaud

Kenny Kin Wong

Ginger Xu-Qiang Yang

John L Humes

Wilson B Knight

James Dellureficio

Stephan K Grant

William A Hanlon

Scott A Polo

Chiragkumar Anilkumar Bhatt

Patrick T Dunn

Amy L Kissinger

Renee Chabin

Raju Mahadev Kharatkar

Jitendra Bhagwandas Kevat

Laurie A Castonguay

Thomas J Lanza

The present invention provides a method for designing a ferric pyrophosphate citrate complex composition containing pyrophosphate, citrate, ferric, sodium, and sulfate ions and calculating and adjusting each salt needed based on a choice of salts that contain the above ions and a desired concentration of each ion in the final product. The present invention also provides a process for preparing a pharmaceutical dosage form of ferric pyrophosphate citrate complex composition in liquid form which is ready to be administrated to patients in need and which maintains the mass balance of ion sources throughout the process.

Preparation of pharmaceutical dosage forms containing iron (III) salts

A process for the preparation and isolation of crystalline miglustat without the use of a column chromatography or ion exchange purification. The crystalline miglustat has a high purity and a melting point of 128&#xb0; C. and an endothermic peak is 133&#xb0; C.

Process for the preparation of high purity miglustat

Knife holder

Container

A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. 

Diazeniumdiolate heterocyclic derivatives

Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. 

Oxadiazole beta carboline derivatives as antidiabetic compounds

A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

Primary amine diazeniumdiolate heterocyclic derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted amides

Bicyclic amides

The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

Substituted imidazoles as cannabinoid receptor modulators

Substituted pyridyoxy amides

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Aralkyl amines as cannabinoid receptor modulators

Substituted furo[2,3-b]pyridine derivatives

Growing community of inventors

Metuchen, NJ, United States of America

Shrenik K Shah